Clinical Trials /

DC Vaccination in CML

NCT02543749

Description:

The aim of this phase I/II trial is induction of anti leukemic T cell immunity in a clinical situation of "minimal residual disease". This might be a strategy to immunologically eradicate the residual leukemia cells. Patients to be included are chronic phase bcr/abl+ CML (chronic myeloid leukemia) patients in stable cytogenetic and/or molecular remission. These patients can be included if they have: 1. not achieved a CMR (complete molecular response) or 2. achieved bcr/abl < 10% on qPCR (quantitative polymerase chain reaction) (=MCyR) (Major cytogenic Response), but less than a CCyR (complete cytogenic Response). Autologous DC (Dendritic cells), generated under GMP (Good manufacturing conditions) conditions, are used as a vaccine. These DC constitutively express all putative tumor antigens. In order to ensure sufficient presentation of distinct CML-related antigens, particularly in good responders to TKIs, DC are additionally pulsed with peptides from bcr/abl, WT-1 (Wilms Tumor Protein) and proteinase-3. Monitoring of T cell reactivity against these peptides can then serve as surrogate marker for anti leukemic immunity induced by the vaccine. Vaccination is performed with 10^7 DC i.d. (intra dermal) in weeks 1, 3, 5, 8, 11, 14, 17, 20, 23 and 26. KLH (keyhole limpet hemocyanin) is used as an adjuvant for vaccine preparations in weeks 3, 5 and 8 (and 11).

Related Conditions:
  • Chronic Myeloid Leukemia
Recruiting Status:

Recruiting

Phase:

Phase 1/Phase 2

Trial Eligibility

Document

Title

  • Brief Title: DC Vaccination in CML
  • Official Title: Dendritic Cells as Autologous Vaccine in Patients With Chronic Myeloid Leukemia

Clinical Trial IDs

  • ORG STUDY ID: CSTI571ADE60
  • SECONDARY ID: 2006-006962-41
  • NCT ID: NCT02543749

Conditions

  • Myeloid Leukemia, Chronic

Interventions

DrugSynonymsArms
DC vaccineDC vaccine

Purpose

The aim of this phase I/II trial is induction of anti leukemic T cell immunity in a clinical situation of "minimal residual disease". This might be a strategy to immunologically eradicate the residual leukemia cells. Patients to be included are chronic phase bcr/abl+ CML (chronic myeloid leukemia) patients in stable cytogenetic and/or molecular remission. These patients can be included if they have: 1. not achieved a CMR (complete molecular response) or 2. achieved bcr/abl < 10% on qPCR (quantitative polymerase chain reaction) (=MCyR) (Major cytogenic Response), but less than a CCyR (complete cytogenic Response). Autologous DC (Dendritic cells), generated under GMP (Good manufacturing conditions) conditions, are used as a vaccine. These DC constitutively express all putative tumor antigens. In order to ensure sufficient presentation of distinct CML-related antigens, particularly in good responders to TKIs, DC are additionally pulsed with peptides from bcr/abl, WT-1 (Wilms Tumor Protein) and proteinase-3. Monitoring of T cell reactivity against these peptides can then serve as surrogate marker for anti leukemic immunity induced by the vaccine. Vaccination is performed with 10^7 DC i.d. (intra dermal) in weeks 1, 3, 5, 8, 11, 14, 17, 20, 23 and 26. KLH (keyhole limpet hemocyanin) is used as an adjuvant for vaccine preparations in weeks 3, 5 and 8 (and 11).

Trial Arms

NameTypeDescriptionInterventions
DC vaccineExperimentalAutologous DC pulsed with leukemia-associated peptides+adjuvant. Ten vaccinations over 26 weeks with 10 x 106 freshly thawed DC Intradermal injections (1-2 ml volume)
  • DC vaccine

Eligibility Criteria

        Inclusion Criteria:

          1. Patients with bcr/abl-positive CML in stable cytogenetic / molecular remission after
             at least 18 months therapy with tyrosine kinase Inhibitors (TKI). The following groups
             of patients will be included:

               -  complete cytogenetic remission (CCyR), but stable detection of bcr/abl-transcript
                  on qPCR (at least on two different time points over a period of at least 6
                  months). A stable molecular remission is assumed, if the difference between the
                  qPCR values does not exceed a factor 5 (< 0,5log).

               -  No CCyR, but qPCR for bcr/abl transcript < 10% (= MCyR (Major cytogenetic
                  Response)) after at least 24 months on 2nd generation TKI therapy.

          2. Treatment with a TKI inhibitor and an additional anti leukemic drug is no exclusion
             criterion.

          3. Age 18-80 years

          4. Performance status of 0 or 1 according to WHO index or Karnofsky index >70 %

          5. Life expectancy > 18 months

          6. Hematological function should be at least partially conserved (platelets count
             >50.000/ μl, Hb > 8g/dl)

          7. written informed consent

          8. No breast feeding

          9. if of childbearing potential, negative pregnancy test (serum/urine ß- HCG ( human
             chorionic gonadotropin )) and willingness to use highly effective contraceptive
             methods (Pearl Index <1, e.g.: birth control pill, loop, hormone implant, transdermal
             hormone patch, a combination of two barrier methods [condom and vaginal diaphragm]
             sterilisation or sexual abstinence) for the study duration and thereafter as long as
             under treatment with antileukemic drugs

        Exclusion Criteria:

          1. Clinically relevant autoimmune disorders

          2. Immunodeficiency syndromes

          3. Known allergy to GM-CSF (granulocyte macrophage colony-stimulating factor), TNF-α
             (Tumor necrosis factor Alpha) , IL-4 (interleukine 4) or KLH (keyhole limpet
             hemocyanin)

          4. Pregnancy (absence confirmed by serum/urine ß-HCG) or breastfeeding

          5. Women of childbearing age without highly effective contraception

          6. Active infectious disease requiring treatment

          7. Continuous therapy with corticosteroids or other immunosuppressive drugs

          8. Severe psychiatric disorders

          9. Organ dysfunction:

               -  Thrombin Time / Partial Thromboplastin Time > 1,5 x upper normal limit

               -  creatinine > 2,0 mg/ml

               -  Bilirubin > 3,0 mg/ml, ALAT/ASAT (Alanine aminotransferase/ aspartate
                  aminotransferase) > 3x upper normal limit

               -  pulmonary disfunction (dyspnea at rest or with minimal exertion)

               -  clinically relevant coronary heart disease or ventricular arrhythmia, congestive
                  heart failure > grade II NYHA (New York Heart Association)

         10. Persons who are detained officially or legally to an official institute

         11. Subjects for whom there is concern about compliance with the protocol procedures

         12. Present History of substance abuse (drug or alcohol) or any other factor (e.g.,
             serious psychiatric condition) that could limit the subject's ability to comply with
             study procedures
      
Maximum Eligible Age:80 Years
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:DC toxicity Parameters using CTC (Common toxicity criteria)
Time Frame:30 weeks
Safety Issue:
Description:Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 (Treatment: long-term vaccination with peptide-pulsed autologous DC in patients with chronic phase CML who have persistent residual cytogenetic and/or molecular disease after at least 18 months therapy with a tyrosine kinase Inhibitor)

Secondary Outcome Measures

Measure:Molecular/cytogenetic Response under vaccination as measured by qPCR for bcr/abl in % IS (International scale)
Time Frame:30 weeks
Safety Issue:
Description:
Measure:T-cell Response: Antigen specific T-cell Response in % CD8+ T-cells for bcr/abl
Time Frame:30 weeks
Safety Issue:
Description:
Measure:T-cell Response: Antigen specific T-cell Response in % CD4+ T-cells for bcr/abl
Time Frame:30 weeks
Safety Issue:
Description:
Measure:T-cell Response: Antigen specific T-cell Response in % CD8+ T-cells for WT-1 (only in HLA-A2+ patients)
Time Frame:30 weeks
Safety Issue:
Description:
Measure:T-cell Response: Antigen specific T-cell Response in % CD8+ T-cells for Proteinase 3 (only in HLA-A2+ patients)
Time Frame:30 weeks
Safety Issue:
Description:

Details

Phase:Phase 1/Phase 2
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Charite University, Berlin, Germany

Trial Keywords

  • CML
  • DC vaccine

Last Updated